Because of increased levels of HIF-1A in the proinflammatory host responses to fungal pathogens, early, selective, and appropriately timed therapeutic modulation of HIF-1A activity might prevent subsequent proinflammatory cascades as a result of anti-PJP therapy that results in organism death and release of highly inflammatory β-glucans [16]. This evidence concerns the gene HIF1A and pneumocystosis.